{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:49:23Z","timestamp":1790567363258,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005851","name":"Shahid Beheshti University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents are the standard of care in DME, a sight-threatening complication of diabetic retinopathy. However, many patients show suboptimal response to anti-VEGF agents alone. This study aimed to investigate the effect of adding interferon alpha 2b eye drops to intravitreal bevacizumab (IVB) in treating patients with DME.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In this double-blind, placebo-controlled, parallel clinical trial, eligible eyes of DME patients were randomized into two treatment arms: (1) three monthly doses of intravitreal bevacizumab (IVB) (2) three monthly doses of IVB plus interferon alpha 2b eye drops (IVB\u2009+\u2009IFN). Outcome measures were changes in central macular thickness (CMT) and best corrected visual acuity (BCVA) over four months. Intraocular pressure (IOP) and possible adverse events were also documented.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 87 eyes of 87 patients with DME were included (mean age: 64.1, female-to-male ratio\u2009~\u20091:1). Anatomical and visual improvements were significant in both groups (<jats:italic>p<\/jats:italic>-value\u2009&lt;\u20090.001). CMT reduction and BCVA improvement were greater in the IVB\u2009+\u2009IFN compared to the IVB group (-117\u00a0\u03bcm vs. -54\u00a0\u03bcm, 0.2 vs. 0.1 LogMAR, <jats:italic>p<\/jats:italic>-values\u2009=\u20090.004 and &lt;\u20090.001, respectively). Final IOP was lower in the IVB\u2009+\u2009IFN group (<jats:italic>p<\/jats:italic>\u2009value\u2009=\u20090.02), but within groups changes were not significant in either arm (<jats:italic>p<\/jats:italic>-value\u2009&gt;\u20090.05). No serious side effects associated with IFN alpha 2b were observed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Adjunction of topical IFN alpha 2b to standard IVB therapy may result in superior functional and structural improvements in eyes with DME in short-term follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>Iranian Registry of Clinical Trials (irct.behdasht.gov.ir), IRCT20230103057035N1, March 18th, 2023.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40942-025-00663-8","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T08:54:25Z","timestamp":1744016065000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Interferon alpha-2b addition to intravitreal bevacizumab for diabetic macular edema: a randomized controlled trial"],"prefix":"10.1186","volume":"11","author":[{"given":"Saeed","family":"Karimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Nouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3146-2438","authenticated-orcid":false,"given":"Amir Reza","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5104-3698","authenticated-orcid":false,"given":"Golnar","family":"Hassanzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hosein","family":"Nouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saber Mohsen","family":"Rikani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed-Hossein","family":"Abtahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"issue":"15","key":"663_CR1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1167\/iovs.64.15.47","volume":"64","author":"TY Wong","year":"2023","unstructured":"Wong TY, Tan TE. The diabetic retinopathy pandemic and evolving global strategies: the 2023 Friedenwald lecture. Invest Ophthalmol Vis Sci. 2023;64(15):47.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"21","key":"663_CR2","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.3390\/cells11213362","volume":"11","author":"J Zhang","year":"2022","unstructured":"Zhang J, Zhang J, Zhang C, Zhang J, Gu L, Luo D, et al. Diabetic macular edema: current understanding, molecular mechanisms and therapeutic implications. Cells. 2022;11(21):3362.","journal-title":"Cells"},{"issue":"7","key":"663_CR3","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.ophtha.2015.03.024","volume":"122","author":"A Das","year":"2015","unstructured":"Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology. 2015;122(7):1375\u201394.","journal-title":"Ophthalmology"},{"issue":"10","key":"663_CR4","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.ophtha.2007.05.062","volume":"114","author":"IU Scott","year":"2007","unstructured":"Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114(10):1860\u20137.","journal-title":"Ophthalmology"},{"key":"663_CR5","doi-asserted-by":"crossref","first-page":"2407037","DOI":"10.1155\/2017\/2407037","volume":"2017","author":"LN Distefano","year":"2017","unstructured":"Distefano LN, Garcia-Arumi J, Martinez-Castillo V, Boixadera A. Combination of Anti-VEGF and laser photocoagulation for diabetic macular edema: A review. J Ophthalmol. 2017;2017:2407037.","journal-title":"J Ophthalmol"},{"issue":"4","key":"663_CR6","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00592-021-01824-5","volume":"59","author":"TC Lin","year":"2022","unstructured":"Lin TC, Chung YC, Hsu TK, Huang HW, Huang YM, Chou YC, et al. Therapeutic effect of simultaneous intravitreal dexamethasone and Aflibercept on diabetic macular edema. Acta Diabetol. 2022;59(4):501\u20138.","journal-title":"Acta Diabetol"},{"issue":"4","key":"663_CR7","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/hep.26657","volume":"59","author":"CR Bolen","year":"2014","unstructured":"Bolen CR, Ding S, Robek MD, Kleinstein SH. Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression. Hepatol Baltim Md. 2014;59(4):1262\u201372.","journal-title":"Hepatol Baltim Md"},{"issue":"5","key":"663_CR8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/jir.2018.0125","volume":"39","author":"N Lewczuk","year":"2019","unstructured":"Lewczuk N, Zdebik A, Bogus\u0142awska J. Interferon alpha 2a and 2b in ophthalmology: A review. J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res. 2019;39(5):259\u201372.","journal-title":"J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res"},{"key":"663_CR9","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D, Group CONSORT. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.","journal-title":"BMJ"},{"issue":"5","key":"663_CR10","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/IAE.0000000000002465","volume":"40","author":"M Afarid","year":"2020","unstructured":"Afarid M, Meshksar A, Salehi A, Safarpour MM, EVALUATION OF THE, EFFECT OF TOPICAL INTERFERON \u03b12b AS A COMPLEMENTARY TREATMENT OF MACULAR EDEMA OF PATIENTS WITH DIABETIC RETINOPATHY. A Double-Blind Placebo-Controlled randomized clinical trial study. Retina Phila Pa. 2020;40(5):936\u201342.","journal-title":"Retina Phila Pa"},{"issue":"1","key":"663_CR11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000508953","volume":"64","author":"M Imazeki","year":"2021","unstructured":"Imazeki M, Noma H, Yasuda K, Motohashi R, Goto H, Shimura M. Anti-VEGF therapy reduces inflammation in diabetic macular edema. Ophthalmic Res. 2021;64(1):43\u20139.","journal-title":"Ophthalmic Res"},{"key":"663_CR12","doi-asserted-by":"crossref","first-page":"2156273","DOI":"10.1155\/2016\/2156273","volume":"2016","author":"P Romero-Aroca","year":"2016","unstructured":"Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R. Diabetic macular edema pathophysiology: vasogenic versus inflammatory. J Diabetes Res. 2016;2016:2156273.","journal-title":"J Diabetes Res"},{"issue":"7","key":"663_CR13","doi-asserted-by":"crossref","first-page":"939","DOI":"10.4239\/wjd.v12.i7.939","volume":"12","author":"BY Li","year":"2021","unstructured":"Li BY, Tan W, Zou JL, He Y, Yoshida S, Jiang B, et al. Role of interferons in diabetic retinopathy. World J Diabetes. 2021;12(7):939\u201353.","journal-title":"World J Diabetes"},{"issue":"3","key":"663_CR14","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1111\/aos.15724","volume":"102","author":"A Hatamnejad","year":"2024","unstructured":"Hatamnejad A, Orr S, Dadak R, Khanani A, Singh R, Choudhry N. Anti-VEGF and steroid combination therapy relative to anti-VEGF mono therapy for the treatment of refractory DME: A systematic review of efficacy and meta-analysis of safety. Acta Ophthalmol (Copenh). 2024;102(3):e204\u201314.","journal-title":"Acta Ophthalmol (Copenh)"},{"issue":"11","key":"663_CR15","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.4103\/ijo.IJO_1465_21","volume":"69","author":"S Mohan","year":"2021","unstructured":"Mohan S, Chawla G, Surya J, Raman R. Intravitreal anti-vascular endothelial growth factor with and without topical non-steroidal anti-inflammatory in centre-involving diabetic macular edema. Indian J Ophthalmol. 2021;69(11):3279\u201382.","journal-title":"Indian J Ophthalmol"},{"issue":"7","key":"663_CR16","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.2337\/dc09-2372","volume":"33","author":"PP Sfikakis","year":"2010","unstructured":"Sfikakis PP, Grigoropoulos V, Emfietzoglou I, Theodossiadis G, Tentolouris N, Delicha E, et al. Infliximab for diabetic macular edema refractory to laser photocoagulation. Diabetes Care. 2010;33(7):1523\u20138.","journal-title":"Diabetes Care"},{"issue":"3","key":"663_CR17","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ophtha.2011.09.008","volume":"119","author":"MA Blasi","year":"2012","unstructured":"Blasi MA, Tiberti AC, Valente P, Laguardia M, Sammarco MG, Balestrazzi A, et al. Intralesional interferon-\u03b1 for conjunctival mucosa-associated lymphoid tissue lymphoma: long-term results. Ophthalmology. 2012;119(3):494\u2013500.","journal-title":"Ophthalmology"},{"issue":"10","key":"663_CR18","doi-asserted-by":"crossref","first-page":"778","DOI":"10.4103\/0301-4738.195013","volume":"64","author":"M Singh","year":"2016","unstructured":"Singh M, Gautam N, Gupta A, Kaur M. Interferon alfa-2b in the management of recurrent conjunctival papillomatosis. Indian J Ophthalmol. 2016;64(10):778\u201380.","journal-title":"Indian J Ophthalmol"},{"issue":"2","key":"663_CR19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/09273948.2012.656877","volume":"20","author":"E Turan-Vural","year":"2012","unstructured":"Turan-Vural E, Acar BT, Acar S. The efficacy of topical interferon alpha 2b treatment in refractory vernal keratoconjunctivitis. Ocul Immunol Inflamm. 2012;20(2):125\u20139.","journal-title":"Ocul Immunol Inflamm"},{"key":"663_CR20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1471-2415-13-63","volume":"13","author":"M Cellini","year":"2013","unstructured":"Cellini M, Balducci N, Strobbe E, Campos EC. Subtenon injection of natural leukocyte interferon \u03b1-2a in diabetic macular edema: a case report. BMC Ophthalmol. 2013;13:63.","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"663_CR21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1006\/mvre.1995.1024","volume":"49","author":"MC Gillies","year":"1995","unstructured":"Gillies MC, Su T. Interferon-alpha 2b enhances barrier function of bovine retinal microvascular endothelium in vitro. Microvasc Res. 1995;49(3):277\u201388.","journal-title":"Microvasc Res"},{"issue":"6","key":"663_CR22","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/jnci\/95.6.437","volume":"95","author":"Z von Marschall","year":"2003","unstructured":"von Marschall Z, Scholz A, Cramer T, Sch\u00e4fer G, Schirner M, Oberg K, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst. 2003;95(6):437\u201348.","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"663_CR23","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1586\/1744666X.2016.1166052","volume":"12","author":"A Maleki","year":"2016","unstructured":"Maleki A, Meese H, Sahawneh H, Foster CS. Progress in the Understanding and utilization of biologic response modifiers in the treatment of uveitis. Expert Rev Clin Immunol. 2016;12(7):775\u201386.","journal-title":"Expert Rev Clin Immunol"},{"issue":"9","key":"663_CR24","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1073\/pnas.0408506102","volume":"102","author":"AK Palucka","year":"2005","unstructured":"Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-\u03b1 in autoimmune diseases. Proc Natl Acad Sci. 2005;102(9):3372\u20137.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"663_CR25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41467-017-02466-4","volume":"9","author":"C Conrad","year":"2018","unstructured":"Conrad C, Di Domizio J, Mylonas A, Belkhodja C, Demaria O, Navarini AA, et al. TNF Blockade induces a dysregulated type I interferon response without autoimmunity in Paradoxical psoriasis. Nat Commun. 2018;9(1):25.","journal-title":"Nat Commun"},{"issue":"21","key":"663_CR26","doi-asserted-by":"crossref","first-page":"6931","DOI":"10.3390\/jcm12216931","volume":"12","author":"N Yamakawa","year":"2023","unstructured":"Yamakawa N, Komatsu H, Usui Y, Tsubota K, Wakabayashi Y, Goto H. Immune mediators profiles in the aqueous humor of patients with simple diabetic retinopathy. J Clin Med. 2023;12(21):6931.","journal-title":"J Clin Med"},{"issue":"Suppl 1","key":"663_CR27","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar2881","volume":"12","author":"GD Kalliolias","year":"2010","unstructured":"Kalliolias GD, Ivashkiv LB. Overview of the biology of type I interferons. Arthritis Res Ther. 2010;12(Suppl 1):S1.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"663_CR28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40942-022-00424-x","volume":"8","author":"H Faghihi","year":"2022","unstructured":"Faghihi H, Inanloo B, Mirzaee A, Fadakar K, Mirshahi A, Ebrahimiadib N, et al. Evaluation of the additive effect of interferon \u03b1 2b with monthly intravitreal injection of bevacizumab in refractory diabetic macular edema. Int J Retina Vitr. 2022;8(1):74.","journal-title":"Int J Retina Vitr"},{"issue":"2","key":"663_CR29","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.3892\/mmr.2014.2772","volume":"11","author":"S Taurone","year":"2015","unstructured":"Taurone S, Ripandelli G, Pacella E, Bianchi E, Plateroti AM, De Vito S, et al. Potential regulatory molecules in the human trabecular meshwork of patients with glaucoma: immunohistochemical profile of a number of inflammatory cytokines. Mol Med Rep. 2015;11(2):1384\u201390.","journal-title":"Mol Med Rep"},{"issue":"2","key":"663_CR30","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1167\/iovs.13-13591","volume":"55","author":"W Huang","year":"2014","unstructured":"Huang W, Chen S, Gao X, Yang M, Zhang J, Li X, et al. Inflammation-related cytokines of aqueous humor in acute primary angle-closure eyes. Invest Ophthalmol Vis Sci. 2014;55(2):1088\u201394.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"663_CR31","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/jamaophthalmol.2015.186","volume":"133","author":"SB Bressler","year":"2015","unstructured":"Bressler SB, Almukhtar T, Bhorade A, Bressler NM, Glassman AR, Huang SS, et al. Repeated intravitreous Ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. JAMA Ophthalmol. 2015;133(5):589\u201397.","journal-title":"JAMA Ophthalmol"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00663-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00663-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00663-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T08:55:35Z","timestamp":1744016135000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-025-00663-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["663"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00663-8","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for this study was granted by the ethics committee of Shahid Beheshti University of Medical Sciences, Tehran, Iran (Approval ID: IR.SBMU.MSP.REC.1401.297). Written informed consent was obtained from all participants prior to the initiation of the study. Confidentiality and anonymity of participants were ensured and maintained throughout the study. This study adhered to the principles of the World Medical Association (WMA) Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}